EnteroBiotix Raises $23.9

Forest

We spent 15+ years in the trenches of corporate innovation, working with companies to help them stay competitive. Then we thought, why not build our own tool? So, for the next several years, we created this super complex innovation management software. It was powerful but hard to use, full of features nobody really needed. And instead of helping people, it seemed to slow them down, including us. That’s when it hit us—maybe we got it wrong. So, we threw it out. Now, we’re trying something different, something simple. Innovation management software that gets out of the way and lets you and your teams innovate. Forest promises 3 things no other innovation platform can: 1. Embedded Support—Your Team’s Trusted Partner With over 15 years of experience in corporate innovation, we’ve been in the trenches and know exactly what it takes to support you. We are an extension of your team, working with you every step of the way. When you need help, you get real answers from real experts who know you and understand your needs. 2. One Low Price—No Tiers, No Hidden Fees We believe in transparency and fairness. That’s why we offer one straightforward price with no hidden fees or upcharges. You get full access to everything you need. No tiered pricing, no extra charges for essential features—just a straightforward, all-inclusive package. 3. Simplicity First—No Unnecessary Complexity We’ve cut out all the unnecessary complexity to give you a platform that’s as intuitive as it gets. Our focus is on making your workflow smoother, not adding more to your plate. Everything we build is designed to be easy, effective, and get you to results faster.

Beauhurst

Beauhurst provides data on every private company in the UK and Germany. Our data covers everything from fundraisings and patents to hiring status and trade data. We help companies to discover, track and understand private companies. We have four data platforms, each built specifically for different industries: BeauhurstAdvise, BeauhurstInvest, BeauhurstImpact, and BeauhurstSales. Book a demo on our website to see the platforms for yourself, or sign up to our newsletter to get weekly insights and regular research reports sent straight to your inbox: beauhurst.com/sign-up-to-the-newsletter. Ranked #318 in the FT 1000: Europe’s Fastest Growing Companies, we’re an energetic, collaborative business, with plans to scale both our product and team this year. Check out our Careers Page to explore current opportunities and learn why our team loves working here.

Dolfin

Dolfin Partners is a specialty finance company providing long-term lease financing for capital expenditures associated with commercial space. The Dolfin Lease is a private, bilateral financing instrument priced on the tenant's credit, not the real estate. Fixed rate. Fully amortizing. Unsecured. Structured from 10 to 20 years to match the useful life of the asset. No collateral pledge. No balloon payment. No refinancing risk. For corporate tenants: Your build-out is a long-term asset. Your financing should be too. If your company is investment-grade or near-IG, you likely qualify. Dolfin finances 100% of your tenant improvements, equipment, and soft costs during construction — converting your capital expenditure into a single, fixed-rate lease at completion. No upfront equity required. No revolver draw. No asset pledge. For improvements already funded, Dolfin reimburses 100% of your sunk costs at close, freeing that capital to be redeployed into your core business. For landlords: Replace your TI equity. Dolfin holds the lease obligation — you hold the space. Non-recourse, no property liens or senior lender approval. New York, NY

Autoimmunity BioSolutions

Autoimmunity BioSolutions (ABS) is pioneering a personalized, genetically guided immuno-corrective therapy designed to normalize or "correct" elevated levels of soluble IL7 receptor (sIL7R), a fundamental driver of poor therapeutic response in autoimmune disease. This therapy targets a genetically defined subpopulation of autoimmune disease patients marked by a highly prevalent genetic variant (SNP) associated with greater severity of disease, increased progression of disease, and poor response to current treatments. This immuno-corrective approach of targeting sIL7R in a genetic population is highly differentiated from current standards of care that rely on immunosuppressive mechanisms and has broad potential to treat numerous autoimmune diseases.

Fractile

Fractile is building chips, systems and software to radically improve the speed and cost of running frontier AI inference. Existing hardware is good for training frontier AI models, but very poorly suited to subsequent inference of the trained model, which is increasingly defining the new era of AI compute workloads. Fractile’s revolutionary approach to fusing computation with memory eliminates this bottleneck, and can scale to allow running the world’s largest models at a global scale. We've rearchitected the inference stack from the ground up - silicon to software - to enable generational leaps in capability on the world’s hardest and most important problems.